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Abstract
Background: A crucial event in Prostate Cancer progression is the conversion from a hormone-
sensitive to a hormone-refractory disease state. Correlating with this transition, androgen receptor
(AR) amplification and mutations are often observed in patients failing hormonal ablation therapies.
β-Catenin, an essential component of the canonical Wnt signaling pathway, was shown to be a
coactivator of the AR signaling in the presence of androgens. However, it is not yet clear what
effect the increased levels of the AR could have on the Wnt signaling pathway in these hormone-
refractory prostate cells.
Results: Transient transfections of several human prostate cancer cell lines with the AR and
multiple components of the Wnt signaling pathway demonstrate that the AR overexpression can
potentiate the transcriptional activities of Wnt/β-Catenin signaling. In addition, the simultaneous
activation of the Wnt signaling pathway and overexpression of the AR promote prostate cancer
cell growth and transformation at castration levels of androgens. Interestingly, the presence of
physiological levels of androgen or other AR agonists inhibits these effects. These observations are
consistent with the nuclear co-localization of the AR and β-Catenin shown by
immunohistochemistry in human prostate cancer samples. Furthermore, chromatin
immunoprecipitation assays showed that Wnt3A can recruit the AR to the promoter regions of
Myc and Cyclin D1, which are well-characterized downstream targets of the Wnt signalling
pathway. The same assays demonstrated that the AR and β-Catenin can be recruited to the
promoter and enhancer regions of a known AR target gene PSA upon Wnt signaling. These results
suggest that the AR is promoting Wnt signaling at the chromatin level.
Conclusion: Our findings suggest that the AR signaling through the Wnt/β-Catenin pathway
should be added to the well established functional interactions between both pathways. Moreover,
our data show that via this interaction the AR could promote prostate cell malignancy in a ligand-
independent manner.
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Background
Prostate cancer is the second leading cause of cancer-
related deaths among men in the U.S., after lung cancer.
Since the prostate gland is an androgen-dependent organ,
prostate cancer initially responds to androgen ablation.
However, this type of treatment is almost never curative,
and the majority of patients will evolve from a hormone-
sensitive to a lethal castration-refractory form of the dis-
ease. It has been postulated that increased levels of both
the androgen receptor (AR) mRNA and protein are associ-
ated with this transition [1-3]. In addition, the AR activat-
ing mutations, as well as coactivator upregulation, were
suggested to be involved in the progression of the disease
to the castration-independent state [4-7]. Single amino
acid substitutions in the AR ligand binding pocket such as
T877A or H874Y, which change the ligand specificities of
the AR, have been reported in patients with castration-
resistant metastatic prostate cancer [8,9]. Major efforts
have been made in prostate cancer research to understand
what role the AR, either amplified wild-type or its differ-
ent mutated versions, plays in these late-stage prostate
cancer cells. Accumulating evidence indicates that various
growth signals and cytokines, such as the insulin-like
growth factor-1, the HER-2/neu tyrosine kinase and the
Wnt/β-Catenin signaling pathways [10-13], can stimulate
the transcriptional activity of the AR.
The Wnt family of signaling proteins plays important
roles in stem cell self-renewal and multiple developmen-
tal processes. Deregulation of Wnt signaling can lead to
various types of cancer [14,15]. The cytoplasmic stabiliza-
tion of β-Catenin, a key component of the canonical Wnt
signaling pathway, and its resulting nuclear accumula-
tion, is a hallmark of the Wnt signaling pathway activa-
tion. In a simplified overview of the canonical Wnt/β-
Catenin pathway, Wnt binds to its receptors Frizzled and
LRP5/6, activating the downstream component Dishev-
elled, which in turn inhibits Glycogen Synthetase Kinase
(GSK-3β), Axin and Adenomatous Polyposis Coli (APC)
in the β-Catenin destruction complex. Once stabilized, β-
Catenin binds to LEF/TCF transcription factors in the
nucleus, and together they activate transcription of the tar-
gets of the Wnt signaling pathway. Stabilizing mutations
of β-Catenin and increased levels of nuclear β-Catenin
have been reported in castration-resistant PCa (recently
reviewed by Yardy and Brewster [16]). It has been shown
that β-Catenin interacts with the AR and potentiates the
AR signaling in an androgen-dependent fashion in pros-
tate cells [17-20]. Therefore, it was suggested that β-Cat-
enin exerts its cancer-related function, in part, through the
AR signaling [13]. On the other hand, the AR signaling
was shown to repress β-Catenin/TCF mediated transcrip-
tion induced by androgen in prostate cancer cells [20-22].
However, the relationship between the AR and β-Catenin
has not been examined in prostate cancer cells exposed to
castration levels of androgens. Recently, TCF4 and GSK-3β
were also shown to interact with the AR in mediating the
AR activity [23]. Therefore, the interaction between the AR
and the entire Wnt signaling pathway needs to be further
explored in order to characterize possible tumor refractory
mechanisms in castration-resistant prostate cancer cells.
Here we show that the AR can potentiate Wnt signaling in
prostate cancer cells. The interaction between the AR and
Wnt signaling provides a growth advantage to prostate
cancer cells at castration levels of androgens. Interestingly,
we found that the presence of the AR ligands attenuated
the input of the AR into the Wnt signaling pathway. Phys-
iological levels of androgens inhibited the tumor cell
growth and transformation mediated by the activation of
the Wnt signaling and the AR overexpression. These
results are in agreement with the observation that the AR
and β-Catenin can co-localize in the nucleus of human
prostate cancer cells. To further explore the mechanism of
the AR and Wnt interaction, we have demonstrated by the
use of Chromatin Immunoprecipitation (ChIP), that Wnt
can recruit the AR and β-Catenin onto the promoter
regions of the Wnt target genes myc and cyclin D1, as well
as to the promoter and enhancer regions of the androgen
target gene PSA. These ChIP results indicate that the AR
potentiates the Wnt signal at the transcriptional level. In
sum, our finding provides a novel mechanism of the AR
function, namely, promoting Wnt/β-Catenin signaling
and its resulting oncogenic properties in prostate cancer
cells at castration levels of androgens.
Results
AR overexpression potentiates Wnt/β-Catenin 
transcriptional activities
While the role of activated Wnt/β-Catenin signaling in
prostate cancer is not entirely clear, recent evidence indi-
cates that β-Catenin contributes to prostate cancer pro-
gression through its enhancement of the AR
transcriptional activity in the presence of androgens [13].
Reciprocally, using transient transfections of prostate can-
cer cells lines, we explored whether the AR overexpression
had any effect on the Wnt/β-Catenin signaling pathway.
As expected, expression of Wnt1 in the prostate cancer
cells PC3 (Figure 1A), CWR22Rv1 and LNCaP (Figure 1B)
resulted in the activation of the luciferase reporter gene
driven by a LEF-dependent promoter [24]. This activation
ranged from 2 to 20 fold compared with control cells
transfected with GFP, depending on the cell type and
assay conditions. The expression of the AR alone had little
effect on LEF-dependent transcription in these cells under
these assay conditions, although the transfection of rela-
tively high amounts of the AR did lead to a 2–5 fold acti-
vation of the reporter gene (data not shown).
Interestingly, the co-expression of Wnt1 and AR resulted
in increased transactivation, compared to the effect ofBMC Cell Biology 2008, 9:4 http://www.biomedcentral.com/1471-2121/9/4
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The overexpression of wild-type or mutant AR potentiates Wnt signaling Figure 1
The overexpression of wild-type or mutant AR potentiates Wnt signaling. Cells grown in RPMI with 10% FBS were 
transiently transfected with indicated plasmids together with LEF-luciferase and pCMV-Renilla reporter constructs in 12 well 
plates. Cotransfection of Wnt1 and AR leads to a synergistic effect on the activation of LEF-luciferase reporter in PC3 cells (A), 
CWR22Rv1 and LNCaP cells (B), compared with transfection with Wnt1 alone. The AR can also potentiate the activation of 
Wnt signaling in cells expressing a constitutively activated human receptor LRP6, truncated at the N terminus (H6ΔN), or a 
stabilized β-Catenin S37A (C). The synergistic effect between AR mutants and Wnt1 signaling is shown (D). AR expression levels 
were measured for both wild type and mutant ARH874Y. Actin levels were used as loading controls. The effect of an AR antago-
nist is shown (E & F). PC3 cells were treated with bicalutamide 4 hours after transfection. Dual luciferase assay was performed 
20–24 hours after treatment.
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Wnt1 alone (7-fold in PC3, 4-fold in CWR22Rv1, and 2.5-
fold in LNCaP cells) (Figure 1A &1B). This effect is more
dramatic in PC3 cells than in CWR22Rv1 and LNCaP
cells, probably due to the fact that PC3 cells have no
detectable levels of the AR expression, while both
CWR22Rv1 and LNCaP cells express endogenous mutant
forms of the AR. We also tested the ability of the AR to
potentiate other signaling components of the Wnt signal-
ing pathway, such as the constitutively activated receptor
LRP6 with a truncated N terminus (LRP6ΔN) [24], or the
stabilized β-Catenin mutant (β-S37ACatenin) [25]. While
the activation of the Wnt/β-Catenin signaling pathway in
PC3 cells transfected with LRP6ΔN led to a 12-fold
increase in the luciferase activity compared with the GFP
control, the co-expression of the AR increased the activity
46-fold compared with LRP6ΔN signaling alone (Figure
1C). Cotransfection of β-S37ACatenin together with the AR
resulted in a 6-fold activity increase in LEF mediated tran-
scription compared with β-S37ACatenin activity alone (Fig-
ure 1C). Similar effects were also observed when the Wnt
signaling pathway was activated by co-expression of
Dishevelled or Casein Kinase I with the AR in PC3 cells. In
this case, the AR enhanced the signaling activity of Dishev-
elled and Casein Kinase I by 6- and 10-fold respectively
(data not shown). Based on these results, we conclude
that the AR can potentiate Wnt transcriptional activity in
prostate cancer cells.
Since CWR22Rv1 cells express mutant forms of ARH874Y
[26], and the LNCaP cells express ART877A  [27], we
explored whether those mutant forms of the AR could also
stimulate Wnt signaling. Wnt1 together with either wild-
type or mutant AR expression constructs were cotrans-
fected into PC3 cells. Indeed, the mutant ARH874Y also
enhanced Wnt1 signaling with at least 5-fold increases
when compared to Wnt1 activity alone, although this
activity was reduced compared with that of the wild-type
AR (Figure 1D). To prove that the difference in activity was
not due to difference in expression, the levels of AR and
ARH874Y  were examined. As shown in Figure 1D, the
expressions of both forms of AR were equivalent. Similar
results were obtained for the ART877A mutation as well
(data not shown). These results indicate that the mutated
AR expression in CWR22Rv1 and LNCaP cells can poten-
tiate Wnt signaling.
To confirm our observation that the AR potentiates Wnt
signaling, bicalutamide was used to determine whether an
AR antagonist could inhibit this potentiation. At concen-
trations as high as 10 μM, bicalutamide did not have any
effect on the transcriptional activities of the LEF-depend-
ent luciferase reporter in PC3 cells when cells were trans-
f e c t e d  w i t h  W n t 1  o r  A R  a l o n e .  H o w e v e r ,  i t  i n h i b i t e d
approximately 60% of the transcriptional activity pro-
moted by the co-expression of the AR and Wnt1 (Figure
1E), suggesting that when bound to an antiandrogen, the
AR is less capable of potentiating Wnt signaling. Noticea-
bly, this inhibition was observed in cells cultured with 5%
charcoal-stripped serum without the addition of an AR
agonist such as 5α-dihydrotestosterone (DHT). This indi-
cates the mechanism by which bicalutamide inhibits the
synergy between Wnt and AR is not likely to be the dis-
placement of an agonist, but rather through the binding
of bicalutamide to the AR. To characterize this inhibition
further, bicalutamide was tested in a dose-dependent
manner with concentrations ranging from 0.1 nM to 25
μM in the LEF-dependent luciferase reporter assay, using
PC3 cells co-transfected with both Wnt1 and AR. Bicaluta-
mide showed an IC50 of 1.38 μM in this study (Figure 1F).
AR interacts with Wnt signaling to promote prostate 
cancer cell proliferation
To investigate whether the synergy between the AR and
Wnt transcriptional activities would lead to accelerated
tumor cell growth, we set out to measure the growth of
PC3 cells under the conditions of overexpressing the AR
alone, Wnt1 alone, or the combination of both. The trans-
fection efficiency was monitored by the expression of a
control GFP. Around 90% of the PC3 cells had green flu-
orescence under a fluorescent microscope, indicating a
high level of transfection in those cells. Cell numbers were
then obtained after seven days post-transfections and
incubation in the absence or presence of 0.1 nM DHT
using Guava technology. As shown in Figure 2A, cells
transfected with either Wnt1 or AR alone do not show sig-
nificant differences in cell numbers compared with con-
trol cells transfected with GFP (p < 0.2) in the absence or
presence of 0.1 nM DHT. However, cotransfection of
Wnt1 and AR increased the number of PC3 cells signifi-
cantly compared with either one of them alone: with AR
(p < 0.005), or with Wnt1 (p < 0.007) in the absence of
DHT; and with AR alone (p < 0.027), or with Wnt alone
(p < 0.003) in the presence of 0.1 nM DHT. These results
suggest that the interaction between these two signaling
pathways at castration levels of androgens promotes pros-
tate cancer cell growth more significantly compared with
the activation of either pathway alone.
We further confirmed this growth stimulation effect in the
parental LNCaP cell line, which expresses an endogenous
ART877A, as well as in an engineered LNCaP-Flag-AR cell
line that also stably expresses a Flag-tagged wild-type AR
(Figure 2B). Since the efficiency of transfection is usually
less than 50% in these cells compared with around 90%
in PC3 cells, we used commercially-available recom-
binant Wnt3A in this set of experiments to ensure the
exposure of Wnt ligand to all cells. In addition, since these
cells tend to cluster, the assessment of proliferation was
carried out by measuring the incorporation of [3H]-thymi-
dine rather than counting cells directly. As expected,BMC Cell Biology 2008, 9:4 http://www.biomedcentral.com/1471-2121/9/4
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LNCaP-Flag-AR cells proliferated faster than LNCaP cells
in both the presence and the absence of Wnt3A treatment
because of the wild-type AR overexpression. As shown in
Figure 2C, the treatment of LNCaP cells with Wnt3A
increased cell proliferation up to 50%, possibly due to the
interaction between the endogenous mutant AR and the
Wnt3A signaling. Furthermore, in the LNCaP-Flag-AR
cells, Wnt3A dramatically increased the cell proliferation
by nearly 100% due to the overexpression of the wild-type
AR. The cells shown in 2C were cultured in charcoal-
stripped serum with no addition of DHT. Similar results
were also obtained in cells exposed to low levels of andro-
gen (such as 0.01 nM and 0.1 nM DHT, data not shown).
Taken together, these results suggest that at castration lev-
els of androgens, the amplified wild-type or mutant AR
can synergistically interact with the Wnt signaling path-
way, resulting in the stimulation of prostate cancer cell
growth.
AR agonists inhibit the AR potentiation of the Wnt 
signaling pathway
We next examined the effect of androgens on the tran-
scriptional synergy between Wnt1 and the AR. As
expected, 10 nM DHT stimulated the AR signaling path-
way, inducing the expression of the luciferase reporter
gene driven by the PSA promoter in PC3 cells transfected
with either the AR, or with both the AR and Wnt (Figure
3A). Interestingly, 10 nM DHT stimulated PSA-luciferase
activity similarly in cells transfected with the AR alone or
with both the AR and Wnt1 (Figure 3A), implying that
additional β-Catenin did not necessarily translate into fur-
ther activation of the AR signaling pathway. On the other
hand, 10 nM DHT inhibited approximately 70% of the
expression of the LEF-driven luciferase reporter in PC3
cells co-transfected with Wnt and AR (Figure 3B). How-
ever, it had no inhibitory effect when cells were trans-
fected with Wnt1 alone (Figure 3B), indicating that
The synergy of Wnt and AR promotes proliferation in prostate cancer cells Figure 2
The synergy of Wnt and AR promotes proliferation in prostate cancer cells. (A) PC3 cells in phenol-red free RPMI 
with 5% charcoal-stripped serum were transfected with the indicated plasmids and treatments in 96 well plates. 7 days after 
transfection, the number of cells was determined with a Guava proliferation assay. Cells transfected with GFP were used as 
control. The percentage of cell numbers was calculated for cells transfected with Wnt or AR or both compared with control 
samples. (B) AR expression and Flag-tagged AR in LNCaP-Flag-AR cells and LNCaP cells were detected by Western blot. Actin 
was used as loading control. (C). LNCaP cells and LNCaP-Flag-AR cells in phenol-red free RPMI with 5% charcoal-stripped 
serum were treated with 100 ng/ml Wnt3A for four days in 96 well plates. The cells were then labelled with [3H]-thymidine 
and harvested to measure the amount of thymidine incorporation. LNCaP cells which received no Wnt3A treatment were 
used as control. The percentage of [3H]-thymidine incorporation was calculated compared with control.
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AR agonists inhibit the Wnt and AR synergy Figure 3
AR agonists inhibit the Wnt and AR synergy. PC3 cells in phenol-red free RPMI with 5% charcoal-stripped serum in 96 
well plates were transfected with the indicated plasmids, together with pCMV-Renilla reporter and PSA-luciferase (A, C, & E) 
or LEF-Luciferase (B, D, & F). The following treatments were applied to cells 4 hours after transfection: 10 nM DHT (A & B); 
10 uM Nilutamide (C & D); 10 uM Bicalutamide (E & F). Dual luciferase assays were performed 20–24 hours after treatment.
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similar to bicalutamide, its mechanism of action is
through binding to the AR. We also noticed that DHT not
only abrogated the AR-Wnt synergy, but also reduced the
LEF-dependent transcription to levels lower than what
was observed in cells transfected only with Wnt 1 (Figure
3B). This may be due to the fact that DHT can recruit β-
Catenin into the AR signaling pathway, an observation
that has been confirmed by other groups [17-20].
In order to confirm that the inhibition of the AR-Wnt
potentiation by any AR ligand is independent of its phar-
macological activity, we explored the effect of nilutamide,
a small non-steroidal molecule that is an agonist of the
mutant ART877A expressed in LNCaP cells and possibly
also an agonist of the mutant ARH874Y  found in the
CWR22 xenograft model [27-30]. As shown in Figure 3C,
nilutamide stimulated the PSA promoter-driven transcrip-
tion of the luciferase reporter when cotransfected with
either the ART877A or the ARH874Y mutants into PC3 cells.
However, it had less of an effect on the wild-type AR-
mediated transcription. This result is consistent with pre-
vious reports [27-30]. In addition, we observed that
nilutamide impeded at least 60% of the LEF-dependent
transcription activity in PC3 cells cotransfected with Wnt1
and either wild-type AR, ART877A, or ARH874Y (Figure 3D).
Recently, bicalutamide was identified as an agonist for the
ARW741L and ARW741C mutations [31]. This effect was con-
firmed in our transactivation assays performed in PC3
cells cotransfected with the mutant AR expression plas-
mids and the PSA promoter-driven luciferase reporter
construct. Bicalutamide indeed stimulated the transcrip-
tional activity through these two particular AR mutants,
but not through the wild-type AR or the LNCaP or CWR22
AR variants (Figure 3E). Bicalutamide also repressed the
synergy between Wnt1 and either the wild type AR or any
of the mutant AR isoforms in PC3 cells (Figure 3F). This
set of experiments demonstrates that AR ligands, agonists,
or antagonists can prevent the AR synergy with the Wnt
signaling pathway.
To further examine the effects of androgens on prostate
cancer growth mediated by the Wnt and AR signaling, we
took advantage of the stable LNCaP-Flag-AR cell line that
overexpresses the wild-type AR (Figure 2B) mimicking the
hormone -refractory state [3]. We examined if this cell line
behaves differently from its parental LNCaP cell line in
the presence or absence of Wnt3A treatment. Cell prolifer-
ation was assessed by measuring [3H]-thymidine incorpo-
ration. Similar to LNCaP cells [32], LNCaP-Flag-AR cells
showed a biphasic response to DHT treatments (Figure
4A). Wnt3A stimulated LNCaP-Flag-AR cell growth
noticeably by 2 fold with 0.01 nM DHT or no DHT treat-
ment. The maximum increase of LNCaP-Flag-AR cell
growth by DHT at 0.5 nM or 1 nM concentration was 4-
fold. Higher concentrations of DHT at 5 nM and 10 nM
reduced cell proliferation by approximately 50% either
with or without Wnt3A treatment (Figure 4A). These
results indicate that normal physiological levels of serum
DHT concentration may inhibit cell proliferation driven
by the AR overexpression and Wnt signaling.
We further confirmed our observation by performing soft
agar growth assays to measure anchorage-independent
growth of LNCaP and LNCaP-Flag-AR cells treated either
with Wnt3A or with DHT. As seen in Figure 4B, LNCaP-
Flag-AR showed an increased soft agar growth compared
with the parental LNCaP cell line. This agrees with past
reports that the AR overexpression increased the onco-
genic malignancy and transformation of prostate cancer
cells. Wnt3A treatment appeared to stimulate colony
numbers on soft agar, but not the colony size. Similarly,
as observed with the cell proliferation assay by [3H]-thy-
midine incorporation in LNCaP-Flag-AR cells, 10 nM
DHT treatment did not stimulate, but rather reduced the
soft agar growth of the LNCaP-Flag-AR cells. When these
cells were treated both with Wnt3A and 10 nM DHT, the
results were similar to that of 10 nM DHT alone (data not
shown). These results suggest that the restoration to phys-
iological levels of androgens could decrease the malignant
tendency of castration-refractory prostate cancer cells,
possibly by inhibiting the input of the AR into the Wnt/β-
Catenin signaling pathway.
AR is promoting Wnt signaling at the chromatin level
Since both the AR and β-Catenin translocate into the
nucleus upon androgen and Wnt signaling respectively,
we performed immunohistochemistry staining using a tis-
sue microarray with the AR and β-Catenin specific anti-
bodies to explore the possible co-localization of the AR
and β-Catenin in human prostate cancer samples. Four
normal prostate tissue samples and nine prostate tumors
were included in this tissue microarray. In the tissue array
tested, the AR expressed at a much higher level in the
tumor samples compared with the normal prostate tis-
sues. In order to observe clear nuclear staining in the
tumor samples, we calibrated the staining to conditions
that gave a very low or negative signal in normal prostate
tissues (Figure 5A). Those conditions revealed a strong
nuclear AR staining in prostate cancer cells with Gleason
Score (GS) 6 (Figure 5C) and above. These studies demon-
strated a considerable AR staining in the nucleus of the
nine tumors. In the meantime, β-Catenin was localized to
the cell membrane in all four normal prostate tissue sam-
ples (Figure 5B), whereas we observed nuclear β-Catenin
staining in three out of nine prostate tumors from patients
with Gleason Score 6 (Figure 5D) and above. Since the
sections of these stainings are consecutive, it is possible to
identify the same cells with both AR and β-Catenin
nuclear staining (see arrows). These results are not only
consistent with the reports that associate high levels ofBMC Cell Biology 2008, 9:4 http://www.biomedcentral.com/1471-2121/9/4
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Wnt-1 and β-Catenin expression with advanced meta-
static, hormone-refractory prostate carcinoma [33,34],
but they also agree with the suggestion of a functional
interaction between the AR and β-Catenin upon co-local-
ization in the nucleus of prostate cancer cells at late stages.
To investigate further the interaction between the AR and
β-Catenin in the nucleus, we examined through chroma-
tin immunoprecipitation assays (ChIP), whether the AR
can be recruited to the promoter region of Wnt target
genes in LNCaP cells. Since it has been shown that Wnt
signaling can activate both Myc and Cyclin D1, which
contain LEF/TCF binding sites in their promoter regions
[35,36], we asked if Wnt signaling could bring the AR to
these regions as well. Indeed, Wnt3A stabilized β-Catenin
and increased its binding to the myc and cyclin D1 pro-
moter regions (Figure 6A, 6B). In addition, the treatment
of LNCaP cells with Wnt3A resulted in the recruitment of
the AR to the promoter regions of both myc and cyclin D1
(Figure 6C, 6D), implying a direct transcriptional involve-
ment of the AR at the promoters of these Wnt target genes
upon activation of Wnt signaling. Interestingly, LNCaP
cells treated with a physiological level of DHT (10 nM)
might have reduced amounts of β-Catenin at the myc and
The effect of DHT on cell proliferation and soft agar growth Figure 4
The effect of DHT on cell proliferation and soft agar growth. (A) LNCaP-Flag-AR cells in phenol-red free RPMI with 
5% charcoal-stripped serum were treated with DHT ranging from 0.01 nM to 10 nM with or without Wnt3A 100 ng/ml for 
four days in 96 well plates. The cells were then labeled with [3H]-thymidine and harvested to measure the thymidine incorpo-
ration. Cells that received no DHT treatment were used as control. The percentage of [3H]-thymidine incorporation was cal-
culated compared with control. (B). LNCaP and LNCaP-Flag-AR cells were plated in soft agar with no treatment as control or 
with 100 ng/ml Wnt3A, or 10 nM DHT. After approximately 4 weeks, colonies were fixed with 10% formaldehyde in PBS. A 
representative field of cells was photographed for each cell type, with or without treatment using bright-field microscopy. 
Upper panel LNCaP or LNCaP-Flag-AR cells received no treatment, while lower panel, LNCaP-Flag-AR cells were either 
treated with Wnt3A or DHT.
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cyclin D1 promoters compared with untreated samples
(Figure 6A, 6B), possibly due to the fact that cell stimula-
tion with DHT causes recruitment of β-Catenin to the pro-
moter and enhancer regions of PSA (Figure 6E, 6F). We
also found that DHT recruited the AR to the myc promoter
and possibly the cyclin D1 promoter in the absence of Wnt
signaling (Figure 6B, 6C), indicating that direct AR bind-
ing sites may be present in these promoter regions. This
finding is in agreement with the report that endogenous
AR was bound to a TCF-4 responsive element in the c-Myc
promoter [37].
We also examined the promoter and enhancer regions of
PSA, a well characterized AR regulated target gene. As
reported [38], DHT treatment promoted the binding of
the AR at both of these regions (Figure 6E, 6F). Interest-
ingly, in the absence of androgens the AR was also
recruited to the PSA promoter and enhancer regions as a
result of Wnt3A signaling (Figure 6E, 6F). This suggests
that upon Wnt stimulation, the stabilized β-Catenin could
bind to the AR, leading to its signaling activation. This was
further confirmed when β-Catenin was found at the pro-
moter and enhancer regions of PSA upon treatment with
Wnt3A (Figure 6G, 6H). These ChIP results demonstrate a
novel mechanism by which Wnt stimulates the transcrip-
tional activity of the AR in the absence of androgens.
Discussion
The androgen receptor signaling pathway has been shown
to play an essential role in castration-refractory prostate
cancer [2,3,39,40]. Recent emerging evidence indicates
that the Wnt/β-Catenin signaling pathway is involved in
advanced prostate cancer [13,33,34,41,42], and it is
known that β-Catenin can signal through the AR in the
presence of androgens. We determined the influence of
the AR on the Wnt/β-Catenin transcriptional activity in
prostate cancer cells with activated Wnt signaling under
conditions that mimic the castration-resistant stage. It was
reported that the mean total serum testosterone concen-
tration and the androgen bioactivity in the serum of nor-
mal men were from 8 nM to 12 nM [43], while the
castration level is below 3 nM [44]. The current study was
conducted using concentrations of androgens similar to
the castration levels in several prostate cancer cell lines.
Our results demonstrated a novel mechanism for the AR
function by potentiating the Wnt signaling pathway to
promote prostate cancer cell growth at the castration lev-
els of androgens. These results are not only consistent
with the report by Verras et al. [42] that Wnt3A condi-
tional medium promotes LNCaP cell growth both in lig-
and-dependent and independent manners, but they also
agree with the observation that Wnt3a stimulated prolif-
eration selectively in the AR positive prostate cancer cells,
but not in AR negative cells [45]. We further observed that
Expression of AR and β-Catenin in normal prostate tissues and tumor samples Figure 5
Expression of AR and β-Catenin in normal prostate tissues and tumor samples. A tissue microarray containing 9 
prostate tumors and 4 normal prostate tissue samples was stained with antibodies against AR and β-Catenin. In normal pros-
tate tissues, the low levels of AR expression, compared with the high levels in prostate cancer cells, were indicated by lack of 
AR staining in cells (A); β-Catenin was predominantly located at the normal cytoplasmic membrane (B). In late stage prostate 
cancer samples, AR was substantially overexpressed in the nuclei of the prostate cancer cells (C) where nuclear β-Catenin 
staining was also observed in some of these cells (D).
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The recruitment of AR and β-Catenin to Wnt signaling target genes as well as PSA promoter and enhancer region using CHIP  analysis Figure 6
The recruitment of AR and β-Catenin to Wnt signaling target genes as well as PSA promoter and enhancer 
region using CHIP analysis. LNCaP cells in phenol-red free RPMI with 5% charcoal-stripped serum were treated with 
either 10 nM DHT, 100 ng/ml Wnt3A, or no treatment for 16 hours before cross-linking. Anti-β-Catenin (A, B, G and H) and 
anti-AR (C, D, E and F) antibodies, together with negative control IgG were then used for immunoprecipitation. After reverse 
crosslinking and DNA purification, PCR products were analyzed using the Agilent 2100 bioanalyzer. Percent of input is shown 
here to compare the levels of β-Catenin or AR at the promoter or enhancer region of PSA, or the promoter region of Cyclin 
D1 or Myc.
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mutant forms of AR have a similar or possibly reduced
ability to stimulate Wnt1/β-Catenin signaling. This find-
ing could offer an explanation for the high incidence of
wild-type AR overexpression observed in advanced castra-
tion-refractory prostate cancer specimens. Our results
demonstrated that both AR agonists and antagonists can
inhibit the positive effects of both the wild-type and
mutant AR isoforms on the Wnt signaling pathway. This
intriguing phenomenon might suggest that the ligand-
bound AR leads to interactions with other cofactors in the
AR signaling pathway[46], therefore reducing the ability
of AR to signal into the Wnt/β-Catenin pathway. One such
complex that involves the AR and its ligands, regardless of
their agonistic or antagonistic nature, is the interaction
with heat shock proteins. Upon ligand binding, the AR is
dissociated from the heat shock complex and binds to
DNA after undergoing dimerization. We can hypothesize
that the potentiation of the AR on the Wnt/β-Catenin sig-
naling pathway requires the presence of components of
the heat shock protein complex, or alternatively that it
requires the AR in its monomeric form in order to com-
plex with β-Catenin as a heterodimer. This could explain
why both the AR agonists and antagonists inhibit the AR
input into the Wnt signaling pathway. In this report, we
demonstrated that physiological levels of DHT reduced
the malignancy of LNCaP cells with the AR overexpres-
sion. This might provide a possible mechanism for the
potential therapeutic benefit of intermittent androgen
suppression. Finally, our mechanistic study showed that
Wnt can signal through the binding of the AR and β-Cat-
enin at the PSA promoter and enhancer regions, indicat-
ing that Wnt-stabilized β-Catenin can promote AR
transcriptional activities under the conditions of andro-
gen ablation. This interesting observation is being further
explored. Since it has been shown that TCF-4 interacts
with the AR directly and that the interaction might occur
on the promoters or enhancers of certain genes [37], the
role of TCF4 in this interaction, as well as the identifica-
tion of the domains of the AR and beta-Catenin involved,
is being investigated.
Previous studies showed that TCF target gene transcrip-
tion can be suppressed by AR in a ligand-dependent man-
ner [20-22]. While two such reports used cell lines other
than prostate cells for their investigation, the work by
Chesire and Isaacs was conducted in a variety of prostate
cancer cells. It is interesting to note that in LAPC-4 cells
that express endogenous wild-type AR, the addition of
increased amounts of androgen did not show any inhibi-
tion on the TCF transcriptional reporter activated by over-
expression of a stabilized β-Catenin mutant. Furthermore,
when DU145 cells were transfected with the wild-type AR
or mutant AR with deleted DNA binding domain (DBD),
an increase of TCF transcriptional activities was observed
[19]. In addition, overexpression of this mutant did not
lead to ligand-dependent interference of TCF transcrip-
tion. These observations are in agreement with what we
have observed in our study. Another aspect that needs to
be considered when comparing our findings with previ-
ous ones is that many of those studies used the β-Catenin
stabilized mutants for the activation of the Wnt signaling
pathway. The level of signaling activation is often very
high using β-Catenin stabilized mutants, and therefore, it
is difficult to observe any synergy between the β-Catenin
stabilized mutants and any other positive regulator of the
pathway. Our study used several positive signaling com-
ponents of the Wnt signaling pathway, such as Wnt1,
truncated LRP6, Dishevelled etc., and the AR potentiation
effects on the luciferase reporter are consistent among
those signaling components. Very recently, it has been
reported that AR protein expression was down-regulated
in the presence of Wnt ligand, although the AR mRNA
level was increased by Wnt signaling [47]. In our study we
have observed that high levels of nuclear AR staining and
β-Catenin staining may co-localize in prostate cancer
cells. This indicates that the mechanism of AR protein
down-regulation by Wnt signaling may not exist in all
prostate cancer cells.
To reach a full understanding of the Wnt/β-Catenin path-
way in prostate cancer, a better comprehension of the spe-
cific role that the Wnt/β-Catenin signaling pathway plays
in normal prostate tissue is required. The Wnt/β-Catenin
pathway has been implicated in the maintenance of stem
or progenitor cells in adult tissues such as blood, intestine,
muscle and mammary glands [48-53]. It was suggested
that a major aspect of β-Catenin signaling in normal pros-
tate physiology is to renew the precursor cells in the basal
compartment of gland acini [13]. The AR is known to be
expressed in differentiated luminal glandular epithelial
cells [54]. The distinct expression patterns indicate that
these two signaling pathways may normally function in
different cell populations (Figure 7A and 7B). In hor-
mone-sensitive prostate cancer cells, the androgen-bound
AR can inhibit the Wnt/β-Catenin signaling [19] (Figure
7C). However, in prostate tumor cells, especially in those
that have adapted to growth in a low androgen environ-
ment, these two signaling pathways could be found aber-
rantly activated, as observed in our studies. We propose
that in castration-refractory prostate cancer cells, the colo-
calization of both AR and β-Catenin enables the AR to sig-
nal through the Wnt/β-Catenin signaling pathway,
leading to a propagation of the already accelerated cell
growth and an increased state of malignancy compared
with the cells that only have one of the two aberrant sign-
aling pathways (Figure 7D).
Conclusion
Since it has been shown that androgen-independent pros-
tate cancer is heterogeneous and multifocal [55,56], it isBMC Cell Biology 2008, 9:4 http://www.biomedcentral.com/1471-2121/9/4
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possible that castration-refractory tumors derive from dif-
ferent combinations of the AR amplification, AR muta-
tions and deregulated signaling pathways. Our data
indicates that in hormone-refractory prostate cancer cells,
the AR signals through the Wnt/β-Catenin pathway to
promote tumor cell malignancy in a ligand-independent
manner. Therapies targeting the input of the AR into the
Wnt signaling pathway may lead to effective treatments
for castration-refractory prostate tumors. Although both
the standard anti-androgens and the androgens tested in
this study can inhibit the input of the AR into the Wnt/β-
Catenin signaling pathway, they can only reduce it to cer-
tain extent without totally abolishing it. It would be con-
ceivable that a new generation of the AR antagonists could
not only repress the AR mediated transcription, but also
effectively disrupt the interaction with other pathways
that can lead to the growth and transformation of castra-
tion-refractory prostate cancer.
Methods
Cell culture and transfection
Prostate cancer cells (PC3, CWR22Rv1 and LNCaP) were
grown in RPMI 1640 medium (Invitrogen) supplemented
with 10% FBS (Invitrogen) and 1% penicillin/streptomy-
cin (Invitrogen) at 37°C in 5% CO2. Cells were plated
into 12 well plates or 96 well plates 16 hours before trans-
fection either in growth medium or, if not specified in the
figure legend, in phenol-red-free RPMI (Invitrogen) with
5% charcoal stripped serum (Hyclone) and 1% penicillin/
streptomycin. Transfections were performed with Fugene
6 (Roche) according to the manufacturer's protocol. For
12 well assays, each well received 0.02 μg of pCMV-LEF-1,
0.1  μg of LEF-luciferase reporter plasmid, and 0.01 μg
pCMV-Renilla together with 0.5 μg each of the expression
plasmids [24]. For 96 well assays, each well received 2 ng
of pCMV-Renilla, 10 ng each expression plasmids, 4 ng of
pCMV-LEF-1 and either 20 ng of the LEF-luciferase
reporter or 35 ng of the PSA-luciferase reporter plasmid.
Working model for the interaction of AR and Wnt/β-Catenin signaling pathway in castration-resistant prostate cancer cells Figure 7
Working model for the interaction of AR and Wnt/β-Catenin signaling pathway in castration-resistant pros-
tate cancer cells. In normal conditions, Wnt and androgen signaling function at different cell populations (A&B). In prostate 
cancer where both pathways may be deregulated in the same cells, androgens may inhibit the input of AR into the Wnt signal-
ing pathway where β-Catenin can potentiate the AR signaling (C). In castration-resistant prostate cancer cells, Wnt can acti-
vate both signaling pathways turning the unliganded AR into a coactivator of the Wnt dependent transcriptional program (D).
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Generation of AR Mutants
From a pCMV-Flag vector containing wild type AR, a 1507
bp fragment was excised utilizing the endogenous BstEII
and SalI restriction sites. This fragment encompasses a
region of the AR gene containing the three mutation sites.
Using the primers listed below and the QuickChange II
Site-Directed Mutagenesis kit (Stratagene), an appropriate
single base pair substitution was generated for each of the
mutants:
H874Y (CAT to TAT):
5' – TTGCGAGAGAGCTGTATCAGTTCACTTTTG – 3' and
5' – CAAAAGTGAACTGATACAGCTCTCTCGCAA – 3'
T877A (ACT TO GCT):
5' – AGCTGCATCAGTTCGCTTTTGACCTGCTAA – 3' and
5' – TTAGCAGGTCAAAAGCGAACTGATGCAGCT – 3'
W741L (TGG to TTG):
5' – ACCATGAGCCCCATCAAGGAGTACTGAAT – 3' and
5' – ATTCAGTACTCCTTGATGGGGCTCATGGT – 3'
W71C (TGG to TGT):
5' – ACCATGAGCCCCATACAGGAGTACTGAAT – 3' and
5' – ATTCAGTACTCCTGTATGGGGCTCATGGT – 3'
These mutant fragments were then cloned into the pCMV-
Flag-AR vector lacking the corresponding 1507 bp wild
type AR region. All of the mutant constructs were verified
by DNA sequencing prior to these studies.
Luciferase assays
Luciferase assays were performed with the dual luciferase
assay kit (Promega) according to the manufacturer's
instructions. The luciferase activities were normalized
with the Renilla luciferase activities. The activity of control
GFP expression was set to 1, and the relative activities to
GFP were then calculated for fold activation. Each experi-
ment was carried out in triplicate with error bars repre-
senting standard deviation. All the experiments were
repeated three times.
Cell growth assay
Guava Viacount: PC3 cells were plated into a 96 well plate
at 1 × 104 cells per well in 100 μl phenol-red free RPMI
with 5% charcoal stripped serum and 1% penicillin/strep-
tomycin. After 24 hours, cells in each well were transfected
with 100 ng of the indicated plasmids. To ensure transfec-
tion with equal amount of DNA, 100 ng of GFP was
cotransfected into each well containing cells receiving
only 100 ng of a single plasmid. Seven days after transfec-
tion, cells were trypsinized and stained with Guava PCA-
96 Viacount reagent (Guava technologies) as indicated by
the manufacturer. Cells were then transferred to a low-
attachment 96 well plate and analyzed by Guava PCA-96
using the Guava ViaCount program. Each experiment was
carried out in triplicate with error bars representing stand-
ard deviation.
[3H]-thymidine incorporation assay: LNCaP cells and
LNCaP-Flag-AR cells were seeded at 6000/well in 96 well
plates and maintained in phenol-red free RPMI medium
supplemented with 5% charcoal-stripped serum. After 24
hours, cells were treated with either 100 ng/ml Wnt3A or
control (PBS with 0.2% serum). Four days after the com-
pound treatment, cells were labeled with [3H]-thymidine
for four to five hours. Plates were then harvested and
counted using TOPCOUNT. Each experiment was carried
out in triplicate with error bars representing standard
deviation and repeated three times.
Statistical Analysis
Comparison of cell numbers in cells transfected with GFP,
Wnt1 or AR alone, as well as Wnt1 and AR together was
conducted using one-tail paired student's t test. P < 0.05
was considered statistically significant.
Soft Agar growth assay
For analysis of anchorage-independent growth of both
treated and untreated parental LNCaP and LNCaP-Flag-
AR cells, a soft agarose medium was employed. 1 × 104
trypsinized cells were resuspended in 1 ml of RPMI con-
taining 10%FBS and 0.3% agarose (type I-A, Sigma) and
layered onto a 0.5 ml cushion of 0.6% agarose in RPMI
supplemented with 10%FBS in 24-well plates (Costar).
The next day, cells were treated with either 10 nM DHT
(Sigma) or 100 ng/mL Wnt3A (R&D Systems) in RPMI
with 5% charcoal-stripped serum. The medium, with or
without treatments, was then renewed by gentle aspira-
tion every 5 days. Cultures were incubated at 37°C in a
humidified incubator containing 5% CO2, and, after an
approximate 4 week growth period, colonies were fixed in
the presence of 10% formaldehyde in PBS. Colony growth
was assessed by photography, noting size and frequency
in a typical field of cells using bright-field microscopy
(12.5×). Each experiment was carried out in duplicate.
And the experiments have been repeated three times.
Immunohistochemistry
A tissue microarray was obtained from Asterand contain-
ing 4 normal prostate tissue and 9 prostate tumors. This
microarray was stained with antibodies against AR (SantaBMC Cell Biology 2008, 9:4 http://www.biomedcentral.com/1471-2121/9/4
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Cruz at a 0.5 ug/ml concentration) and β-Catenin (BD
Biosciences, diluted at 1:500), using consecutive slides for
the two antibodies. For antigen retrieval, Citra Plus Solu-
tion (BioGenex) was used at 95°C for 15 minutes. Slides
were stained using the BioGenex i6000 automated stain-
ing system. The DAKO Envision Plus kit was used for
chromagen detection. As negative controls, isotype mouse
IgG1 and rabbit IgG1 were used, and no staining was
observed (data not shown).
Chromatin Immunoprecipitation Assay
LNCaP cells in RPMI with 5% charcoal-stripped serum
and 1% Pen-Strep were treated with either 10 nM DHT
(Sigma), 100 ng/mL Wnt3A (R&D Systems), or left
untreated. After 16 hours the cells were fixed with 2% for-
maldehyde followed by lysis in 0.2 ml buffer (50 mM Tris
pH 8, 10 mM EDTA, 1% SDS, protease inhibitors) per 1 ×
106 cells. After sonication and centrifugation, the superna-
tant was diluted 1:10 in IP Buffer (16.7 mM Tris-HCl pH
8, 167 mM NaCl, 1.2 mM EDTA, 1.1% Triton ×-100, pro-
tease inhibitors) for immunoprecipitation with either
anti-AR polyclonal antibody (custom made) or anti-β Cat-
enin mouse monoclonal antibody (Cell Signaling) as well
as negative control mouse IgG or rabbit IgG antibodies.
No signals were observed in negative controls (data not
shown). After overnight incubation at 4°C, protein-DNA
complex was then purified with 50 uL of Ultralink Immo-
bilized Protein A/G beads (Pierce) followed by reverse
crosslinking. DNA was then isolated using a Qiagen puri-
fication kit and eluted in 35 ul volumes. Typically, 2 uL of
the purified DNA was used as template in the PCR reac-
tions. The PCR products were analyzed using a Bioana-
lyzer 2100 (Agilent) and a DNA 1000 kit (Agilent). The
amount of PCR product was compared with the input
amount to calculate the percentages of input. This experi-
ment was repeated three times and the average of percent
input was plotted with error bars representing standard
deviation.
The primers used were:
negative control β-Actin [57] (No signal was observed in
AR IP and β-Catenin IP in Figure 6),
forward 5'-TCCTCCTCTTCCTCAATCTCG-3'
reverse 5'-AAGGCAACTTTCGGAACGG-3'
PSA Promoter and enhancer [38]
forward 5'-TCCTGAGTGCTGGTGTCTTAG-3'
reverse 5'-GCCCTATAAAACCTTCATTCCCC-3',
forward 5'-ATGTTCACATTAGTACACCTTGCC-3'
reverse 5'-TCTCAGATCCAGGCTTGCTTACTGTC-3'
human c-myc and cyclin D1 promoter regions [37],
forward 5'-GCTCTCCACTTGCCCCTTTTA-3'
reverse 5'-GTTCCCAATTTCTCAGCC-3'
forward 5'-GGGAGGAATTCACCCTGAAA-3'
reverse 5'-CCTGCCCCCAAATTAAGAAAA-3'.
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